Are there too many antibody-focused companies? There are only so many antibody targets by virtue of their limitations (no intracellular targets). You have JNJ-US, ROG-VX, NOVN-VX, LLY, BMY, SAN-FP, MRK-DE, AMGN, AZN-LN, REGN, GEN-DC, ALXN, SGEN, MOR-DE, MGNX, ANAB, XOMA, etc. Once a target is of interesting, everyone can make one relatively similar product and trial it. There are a lot of potential targets, so does that shift the game to disease biology where are there actually very few intelligent players? Clinical execution is obviously important as well. Maybe we can do an analysis of all new antibody candidates and see how long it took for a fast-follower/competitor to show up…?
Doing this analysis now. My preliminary conclusion after looking at about 200 antibodies is despite the expected chase of exciting targets, there is a lot of stalling and usually more than enough room for multiple entrants. Now, about that biologics capacity…
RIP $VTL, you will be missed.
Wow, BAYN.DE really falling apart.
It will definitely be interesting to see changes in Chinese drug revenue. If you try and look at Sino (1177), it kinda looks like there is a lot of revenue growth (30% y/y) but it’s hard to tell how much is organic. Jiangsu Hengrui is all in Mandarin 🙁 otherwise I’d really like to understand that megacap ($40bn!).
Cannabis-related stocks are or will be epic shorts soon.
I’ve been working on predictive scoring functions for NFL games. I like the Ravens!
Wishing Lil’ Wayne luck on a successful release of “THA CARTER V” — everyone go buy it!
Make sure you follow by official instagram @martinshkreli15 — which my friend Taylor is now managing (thank you, trap queen!)
Sorry I haven’t posted in a while. I was (and still am) busy reading about rare diseases.
I’ve decided to play the Scandinavian after 1. e4 after failing miserably at the French. 1…d5 seems dynamic and tricky, more well-suited to my personality. Wish me luck!